<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402597</url>
  </required_header>
  <id_info>
    <org_study_id>CR013417</org_study_id>
    <secondary_id>39039039ACS2001</secondary_id>
    <nct_id>NCT00402597</nct_id>
    <nct_alias>NCT01151332</nct_alias>
  </id_info>
  <brief_title>Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent
      acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the
      occurrence of death, myocardial infarction (heart attack), repeat myocardial infarctions,
      stroke, and ischemia (inadequate blood supply to a local area) in patients with recent ACS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (patients will be assigned to study treatment by chance), double-blind
      (neither the patient nor the study doctor will know the identity of the assigned study
      treatment) study to evaluate the safety and efficacy of rivaroxaban (study drug) compared to
      placebo (a tablet identical in appearance to study drug but contains no active drug) in
      patients with acute coronary syndrome (ACS [a condition where blood flow in a blood vessel in
      the heart is restricted because of a blood clot]). Rivaroxaban is a drug that acts as a blood
      thinner and is being tested to see if it will be safe and effective in patients diagnosed
      ACS. The goal of this study is to identify the dose and dosing schedule (once-a-day or
      twice-a-day dosing) of rivaroxaban that will be safe and effective in preventing adverse
      cardiovascular outcomes such as death, myocardial infarctions (MI) including repeat
      myocardial infarction (reMI), stroke, or ischemia (inadequate blood supply to a local area)
      requiring revascularization (ie, the re-establishment of blood supply to a part or an organ)
      in patients with ACS who are receiving antiplatelet therapy (ie, aspirin alone or aspirin
      plus an approved thienopyridine, a type of drug such as clopidogrel that acts to inhibit the
      formation of blood clots). Approximately 3500 patients are planned to participate in the
      study for approximately 7 months. At study entry, all patients who are currently receiving
      treatment for ACS with antiplatelet therapy will be permitted to continue this therapy during
      the study. Patients will be enrolled and randomized to receive placebo, rivaroxaban
      administered as a once-daily dose, or rivaroxaban administered as a twice-daily dose at each
      dose level of rivaroxaban tested. Patients randomized at each dose level will continue to
      receive the same treatment for 6 months. Near the end of enrollment at the first dose level,
      available safety and efficacy data from patients will be assessed by an Operations Committee
      before enrolling and randomizing additional patients to the next higher dose level of
      rivaroxaban. Increasing dose levels of rivaroxaban are planned; however, progression to each
      higher dose level will be at the discretion of the Operations Committee. Patient safety will
      be monitored by evaluating adverse events reported, results from clinical laboratory tests,
      findings from electrocardiograms (ECGs) and vital signs measurements, findings from physical
      examinations, and the number of patients with protocol-defined major or minor bleeding, or
      bleeding requiring medical attention. All patients will take study drug or placebo tablets
      orally (by mouth) twice daily for 6 months starting at an initial total daily dose of 5 mg.
      Both once- and twice-daily dosing regimens will be tested at each rivaroxaban dose level
      planned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety)</measure>
    <time_frame>Day 1 to Day 210</time_frame>
    <description>The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Composite Endpoint of All Cause Death, Myocardial Infarction (MI) (Including Repeat MI), Stroke (Ischemic, Hemorrhagic or Unknown), or Severe Recurrent Ischemia Requiring Revascularization (Primary Efficacy)</measure>
    <time_frame>Day 1 to Day 210</time_frame>
    <description>The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Composite Endpoint of Death (All Cause), Myocardial Infarction (MI) (or Repeat MI), or Stroke</measure>
    <time_frame>Day 1 to Day 210</time_frame>
    <description>The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Composite Endpoint of Cardiovascular Death, Myocardial Infarction (MI), or Stroke</measure>
    <time_frame>Day 1 to Day 210</time_frame>
    <description>The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Deaths (All Cause)</measure>
    <time_frame>Day 1 to Day 210</time_frame>
    <description>The number of patients who died due to any cause from the time of randomization to the last date of patient contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Composite Endpoint of Death (All Cause), MI (or reMI), Stroke, Severe Recurrent Ischemia Requiring Revascularization, or Thrombolysis in Myocardial Infarction (TIMI) (Major or Minor Bleeding) to Assess the Net Clinical Benefit</measure>
    <time_frame>Day 1 to Day 210</time_frame>
    <description>The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3490</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 placebo tablet twice daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban/Placebo</intervention_name>
    <description>1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo tablet twice daily for 6 months.</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have symptoms suggestive of ACS that lasted at least 10 minutes at rest occurring
             within 7 days of randomization

          -  Have a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial
             infarction/unstable angina (ie, chest pain or discomfort) (ST elevation is an abnormal
             finding from an ECG test) with at least 1 protocol-defined high risk feature

        Exclusion Criteria:

          -  Active bleeding or high risk of bleeding or intracranial hemorrhage (bleeding within
             the skull enclosing the brain)

          -  Need for continued anticoagulant therapy

          -  Significantly impaired renal (kidney) or hepatic (liver) function

          -  Severe concomitant diseases such as cardiogenic shock (heart damage that results in
             insufficient blood supply to other parts or organs of the body), refractory
             ventricular arrhythmias (irregular contractions of the heart unresponsive to
             treatment), or any severe condition that would limit life expectancy of the patient to
             less than 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.</citation>
    <PMID>19539361</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>July 25, 2012</results_first_submitted>
  <results_first_submitted_qc>July 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2012</results_first_posted>
  <disposition_first_submitted>April 21, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 21, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 28, 2011</disposition_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <name_title>VP FRANCHISE MED LDR</name_title>
    <organization>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L.C.</organization>
  </responsible_party>
  <keyword>Acute Coronary Syndrome (ACS)</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Rivaroxaban (BAY59-7939)</keyword>
  <keyword>Anti-platelet agents</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Thienopyridine</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>NCT00402597: Study 39039039ACS2001 (ATLAS ACS TIMI 46 Trial) was conducted at 297 centers in 27 countries between 17 November 2006 and 19 September 2008. A total of 3576 patients were screened for study and 3491 patients were randomly assigned to treatment.</recruitment_details>
      <pre_assignment_details>Of the 3576 patients screened for study, 85 patients were screening failures and 3491 patients were randomly assigned to treatment. All randomized patients were included in the intent-to-treat (ITT) analysis set and were eligible for efficacy analyses. Of the 3491 patients, 29 never took study drug, leaving 3462 patients valid for safety analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>One placebo tablet twice daily for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Riva 5 mg Total Daily Dose (TDD)</title>
          <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily)</description>
        </group>
        <group group_id="P3">
          <title>Riva 10 mg TDD</title>
          <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
        </group>
        <group group_id="P4">
          <title>Riva 15 mg TDD</title>
          <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
        </group>
        <group group_id="P5">
          <title>Riva 20 mg TDD</title>
          <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1153"/>
                <participants group_id="P2" count="307"/>
                <participants group_id="P3" count="1046"/>
                <participants group_id="P4" count="353"/>
                <participants group_id="P5" count="603"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="962"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="834"/>
                <participants group_id="P4" count="279"/>
                <participants group_id="P5" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="212"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="124"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>One placebo tablet twice daily for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Riva 5 mg Total Daily Dose (TDD)</title>
          <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily)</description>
        </group>
        <group group_id="B3">
          <title>Riva 10 mg TDD</title>
          <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Riva 15 mg TDD</title>
          <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
        </group>
        <group group_id="B5">
          <title>Riva 20 mg TDD</title>
          <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1153"/>
            <count group_id="B2" value="307"/>
            <count group_id="B3" value="1046"/>
            <count group_id="B4" value="353"/>
            <count group_id="B5" value="603"/>
            <count group_id="B6" value="3462"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="847"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="786"/>
                    <measurement group_id="B4" value="283"/>
                    <measurement group_id="B5" value="458"/>
                    <measurement group_id="B6" value="2592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="260"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="145"/>
                    <measurement group_id="B6" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="9.58"/>
                    <measurement group_id="B2" value="58.1" spread="9.76"/>
                    <measurement group_id="B3" value="57.2" spread="9.71"/>
                    <measurement group_id="B4" value="56.4" spread="9.38"/>
                    <measurement group_id="B5" value="57.4" spread="9.06"/>
                    <measurement group_id="B6" value="57.4" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="228"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="143"/>
                    <measurement group_id="B6" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="881"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="818"/>
                    <measurement group_id="B4" value="286"/>
                    <measurement group_id="B5" value="460"/>
                    <measurement group_id="B6" value="2674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea (South)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="124"/>
                    <measurement group_id="B6" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="82"/>
                    <measurement group_id="B6" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety)</title>
        <description>The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention.</description>
        <time_frame>Day 1 to Day 210</time_frame>
        <population>The safety population consisted of all randomized patients who took at least 1 dose of study medication after randomization during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet twice daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Riva 5 mg Total Daily Dose (TDD)</title>
            <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Riva 10 mg TDD</title>
            <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Riva 15 mg TDD</title>
            <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Riva 20 mg TDD</title>
            <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety)</title>
          <description>The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention.</description>
          <population>The safety population consisted of all randomized patients who took at least 1 dose of study medication after randomization during the double-blind treatment period.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1153"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="1046"/>
                <count group_id="O4" value="353"/>
                <count group_id="O5" value="603"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Composite Endpoint of All Cause Death, Myocardial Infarction (MI) (Including Repeat MI), Stroke (Ischemic, Hemorrhagic or Unknown), or Severe Recurrent Ischemia Requiring Revascularization (Primary Efficacy)</title>
        <description>The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact.</description>
        <time_frame>Day 1 to Day 210</time_frame>
        <population>The intent-to-treat (ITT) population consisted of all patients who were randomized to treatment, regardless of study drug intake.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet twice daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Riva 5 mg Total Daily Dose (TDD)</title>
            <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Riva 10 mg TDD</title>
            <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Riva 15 mg TDD</title>
            <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Riva 20 mg TDD</title>
            <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite Endpoint of All Cause Death, Myocardial Infarction (MI) (Including Repeat MI), Stroke (Ischemic, Hemorrhagic or Unknown), or Severe Recurrent Ischemia Requiring Revascularization (Primary Efficacy)</title>
          <description>The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact.</description>
          <population>The intent-to-treat (ITT) population consisted of all patients who were randomized to treatment, regardless of study drug intake.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1160"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="1056"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Composite Endpoint of Death (All Cause), Myocardial Infarction (MI) (or Repeat MI), or Stroke</title>
        <description>The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact.</description>
        <time_frame>Day 1 to Day 210</time_frame>
        <population>The ITT population consisted of all patients who were randomized to treatment, regardliess of study drug intake.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet twice daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Riva 5 mg Total Daily Dose (TDD)</title>
            <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Riva 10 mg TDD</title>
            <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Riva 15 mg TDD</title>
            <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Riva 20 mg TDD</title>
            <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite Endpoint of Death (All Cause), Myocardial Infarction (MI) (or Repeat MI), or Stroke</title>
          <description>The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact.</description>
          <population>The ITT population consisted of all patients who were randomized to treatment, regardliess of study drug intake.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1160"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="1056"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Composite Endpoint of Cardiovascular Death, Myocardial Infarction (MI), or Stroke</title>
        <description>The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact.</description>
        <time_frame>Day 1 to Day 210</time_frame>
        <population>The ITT population consisted of all patients who were randomized to treatment regardless of study drug intake.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet twice daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Riva 5 mg Total Daily Dose (TDD)</title>
            <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Riva 10 mg TDD</title>
            <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Riva 15 mg TDD</title>
            <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Riva 20 mg TDD</title>
            <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite Endpoint of Cardiovascular Death, Myocardial Infarction (MI), or Stroke</title>
          <description>The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact.</description>
          <population>The ITT population consisted of all patients who were randomized to treatment regardless of study drug intake.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1160"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="1056"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Deaths (All Cause)</title>
        <description>The number of patients who died due to any cause from the time of randomization to the last date of patient contact.</description>
        <time_frame>Day 1 to Day 210</time_frame>
        <population>The ITT population consisted of all patients who were randomized to treatment, regardless of study drug intake.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet twice daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Riva 5 mg Total Daily Dose (TDD)</title>
            <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Riva 10 mg TDD</title>
            <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Riva 15 mg TDD</title>
            <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Riva 20 mg TDD</title>
            <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Deaths (All Cause)</title>
          <description>The number of patients who died due to any cause from the time of randomization to the last date of patient contact.</description>
          <population>The ITT population consisted of all patients who were randomized to treatment, regardless of study drug intake.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1160"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="1056"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Composite Endpoint of Death (All Cause), MI (or reMI), Stroke, Severe Recurrent Ischemia Requiring Revascularization, or Thrombolysis in Myocardial Infarction (TIMI) (Major or Minor Bleeding) to Assess the Net Clinical Benefit</title>
        <description>The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban.</description>
        <time_frame>Day 1 to Day 210</time_frame>
        <population>The ITT population consisted of all patients who were randomized to treatment, regardless of study drug intake.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet twice daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Riva 5 mg Total Daily Dose (TDD)</title>
            <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Riva 10 mg TDD</title>
            <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Riva 15 mg TDD</title>
            <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Riva 20 mg TDD</title>
            <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite Endpoint of Death (All Cause), MI (or reMI), Stroke, Severe Recurrent Ischemia Requiring Revascularization, or Thrombolysis in Myocardial Infarction (TIMI) (Major or Minor Bleeding) to Assess the Net Clinical Benefit</title>
          <description>The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban.</description>
          <population>The ITT population consisted of all patients who were randomized to treatment, regardless of study drug intake.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1160"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="1056"/>
                <count group_id="O4" value="356"/>
                <count group_id="O5" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only Treatment-Emergent Adverse Events are presented in the following sections, called as Frequent Adverse Events and Serious Adverse Events</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>One placebo tablet twice daily for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Riva 5 mg Total Daily Dose (TDD)</title>
          <description>Rivaroxaban 5 mg (2.5 mg twice a day or 5 mg once daily) for 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Riva 10 mg TDD</title>
          <description>Rivaroxaban 10 mg (5 mg twice a day or 10 mg once daily) for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Riva 15 mg TDD</title>
          <description>Rivaroxaban 15 mg (7.5 mg twice a day or 15 mg once daily) for 6 months.</description>
        </group>
        <group group_id="E5">
          <title>Riva 20 mg TDD</title>
          <description>Rivaroxaban 20 mg (10 mg twice a day or 20 mg once daily) for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="128" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Normochromic Normocytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Arteriospasm Coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Artery Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Dressler's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Intracardiac Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Parasystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Postinfarction Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Endocardial Fibroelastosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Thyroid Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Retinal Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Oesophageal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Small Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Catheter Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Injection Site Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Puncture Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cellulitis Orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cellulitis Pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gingival Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Implant Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Implantable Defibrillator Malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>In-Stent Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Thrombosis in Device</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Arteriogram Coronary</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Chest X-Ray Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Occult Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Arthritis Reactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Back Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer in Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Colon Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ovarian Granulosa-Theca Cell Tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ovarian Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ischaemic Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Motor Neurone Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Progressive Supranuclear Palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Alcohol Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Drug Dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Renal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Catheterisation Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Arterial Stent Insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Coronary Revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Elective Procedure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Implantable Defibrillator Insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Percutaneous Coronary Intervention</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Aortic Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Iliac Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="223" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="293" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="148" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="1046"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="353"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="603"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP FRANCHISE MED LDR</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L.C.</organization>
      <phone>1 908 927 7767</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

